Cytokinetics to Host Investor Event Following Presentation of Results from ATOMIC-AHF at the European Society of Cardiology Congress 2013
(Thomson Reuters ONE) -
South San Francisco, CA, August 14, 2013 - Cytokinetics, Incorporated (Nasdaq:
CYTK) announced today its plans to host an Investor Event following the
presentation of the results from the ATOMIC-AHF trial at the European Society of
Cardiology Congress 2013. The Cytokinetics event will be held on Tuesday,
September 3(rd) from 2:00 PM - 3:00 PM Central European Time. The event will be
held in the Algiers Room, Village 4 at the RAI Convention Center in Amsterdam,
Netherlands.
Cytokinetics will be represented by Robert Blum, President and Chief Executive
Officer; Dr. Fady I. Malik, Senior Vice President, Research and Early
Development; and Dr. Andrew A. Wolff, Senior Vice President of Clinical Research
and Development and Chief Medical Officer. Also participating will be Dr. John
R. Teerlink, Director of the Heart Failure Program and of the Clinical
Echocardiography Laboratory at the San Francisco Veterans Affairs Medical
Center, California, and Dr. John J.V. McMurray, Professor of Medical Cardiology
at the University of Glasgow, Scotland, United Kingdom.
Presentations and accompanying slides will be simultaneously webcast beginning
at 2:00 PM Central European Time (8:00 a.m. Eastern Time) and can be accessed
through the Investor Relations section of the Cytokinetics' website at
www.cytokinetics.com. The live audio of the forum will also be accessible via
telephone to investors, members of the news media and the general public by
dialing either (866) 999-CYTK (2985) (United States and Canada) or (706)
679-3078 (International) and typing in the passcode 31517709.
An archived replay of the webcast will be available on the Presentations page in
the Investor Relations section of Cytokinetics' website until September
10, 2013. The replay will also be available via telephone from September
3, 2013 at 2:00 p.m. Eastern Time until September 10, 2013 by dialing (855)
859-2056 (United States and Canada) or (404) 537-3406 (International) and typing
in the passcode 31517709.
About Cytokinetics
Cytokinetics is a clinical-stage biopharmaceutical company focused on the
discovery and development of novel small molecule therapeutics that modulate
muscle function for the potential treatment of serious diseases and medical
conditions. Cytokinetics' lead drug candidate from its cardiac muscle
contractility program, omecamtiv mecarbil, is in Phase II clinical development
for the potential treatment of heart failure. Amgen Inc. holds an exclusive
license worldwide to develop and commercialize omecamtiv mecarbil and related
compounds, subject to Cytokinetics' specified development and commercialization
participation rights. Cytokinetics is independently developing tirasemtiv, a
fast skeletal muscle activator, as a potential treatment for diseases and
medical conditions associated with neuromuscular dysfunction. Tirasemtiv is
currently the subject of a Phase II clinical trials program and has been granted
orphan drug designation and fast track status by the U.S. Food and Drug
Administration and orphan medicinal product designation by the European
Medicines Agency for the potential treatment of amyotrophic lateral sclerosis, a
debilitating disease of neuromuscular impairment. Cytokinetics is collaborating
with Astellas Pharma Inc. to develop CK-2127107, a skeletal muscle activator
structurally distinct from tirasemtiv, for non-neuromuscular indications. All of
these drug candidates have arisen from Cytokinetics' muscle biology focused
research activities and are directed towards the cytoskeleton. The cytoskeleton
is a complex biological infrastructure that plays a fundamental role within
every human cell. Additional information about Cytokinetics can be obtained at
www.cytokinetics.com.
This press release contains forward-looking statements for purposes of the
Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics
disclaims any intent or obligation to update these forward-looking statements,
and claims the protection of the Act's safe harbor for forward-looking
statements. Examples of such statements include, but are not limited to,
statements relating to planned presentations, and the properties and potential
benefits of Cytokinetics' drug candidates. Such statements are based on
management's current expectations, but actual results may differ materially due
to various risks and uncertainties, including, but not limited to, potential
difficulties or delays in the development, testing, regulatory approval and
production of Cytokinetics' drug candidates and potential drug candidates that
could slow or prevent clinical development or product approval, including risks
that current and past results of clinical trials or preclinical studies may not
be indicative of future clinical trials results and that Cytokinetics' drug
candidates and potential drug candidates may have unexpected adverse side
effects or inadequate therapeutic efficacy. For further information regarding
these and other risks related to Cytokinetics' business, investors should
consult Cytokinetics' filings with the Securities and Exchange Commission.
Contact:
Cytokinetics, Inc.
Joanna L. Goldstein (Investors & Media)
(650) 624-3000
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Cytokinetics, Inc. via Thomson Reuters ONE
[HUG#1723125]
Unternehmensinformation / Kurzprofil:
Datum: 14.08.2013 - 22:00 Uhr
Sprache: Deutsch
News-ID 287989
Anzahl Zeichen: 6513
contact information:
Town:
SOUTH SAN FRANCISCO
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 194 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Cytokinetics to Host Investor Event Following Presentation of Results from ATOMIC-AHF at the European Society of Cardiology Congress 2013"
steht unter der journalistisch-redaktionellen Verantwortung von
Cytokinetics, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
